Andre Goy, M.D., M.S., is an internationally renowned clinician and researcher of all types of lymphoma, including Hodgkin’s disease, non-Hodgkin’s lymphoma and HIV-associated lymphoma. As chief of John Theurer Cancer Center’s Division of Lymphoma, he leads New Jersey’s largest program for research, treatment and management of lymphoma. Dr. Goy has trained and/or worked at some of the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, M.D. Anderson Cancer Center, University Hospitals Group of Paris and The Pasteur Institute.
Dr. Goy was instrumental in developing John Theurer Cancer Center’s Tissue Bank, where samples of cells, tissue and other anatomical structures are stored and analyzed for research purposes. The Tumor Bank has received more than 1,600 patient consents since it launched.
Dr. Goy is widely-known for his work showing the first evidence of activity of bortezomib in mantle cell lymphoma and then as co-principal investigator on the PINNACLE trial, which led to the U.S. Food & Drug Administration’s approval of VELCADE® (bortezomib) for relapsed / refractory mantle cell lymphoma patients in 2006. He also took part in the original pilot study for RITUXAN® (rituximab), which has been widely used to treat lymphomas, leukemias and autoimmune disorders.
Dr. Goy’s research centers on developing novel targeted therapies for lymphoma and developing biomarkers for lymphoma. He has been invited to speak and teach around the world, and his research has been published extensively.
